IRIS
Ingrasciotta, Ylenia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 897
NA - Nord America 765
AS - Asia 209
Totale 1.871
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 765
IE - Irlanda 373
SE - Svezia 238
IT - Italia 119
VN - Vietnam 106
CN - Cina 97
PL - Polonia 66
DE - Germania 34
BE - Belgio 22
RO - Romania 15
FI - Finlandia 11
NL - Olanda 7
FR - Francia 4
GB - Regno Unito 4
UA - Ucraina 4
IN - India 2
KR - Corea 1
SA - Arabia Saudita 1
TH - Thailandia 1
TW - Taiwan 1
Totale 1.871
Salva come PNG Salva come JPEG
Città #
Dublin 373
Chandler 313
Nyköping 136
Dong Ket 106
Warsaw 66
Messina 62
Princeton 50
Medford 41
Beijing 33
Ann Arbor 32
Bremen 29
Des Moines 25
Brussels 22
Jacksonville 17
Focsani 15
Boardman 10
Cambridge 10
Dearborn 10
Rome 10
Tianjin 9
Wilmington 9
Falls Church 8
Ningbo 6
Caltagirone 5
Frankfurt am Main 5
Shenyang 5
Jinan 4
Nanjing 4
Taizhou 4
Guangzhou 3
Haikou 3
Jiaxing 3
Lancaster 3
Milan 3
Nanchang 3
Redwood City 3
Salerno 3
Zhengzhou 3
Amsterdam 2
Ashburn 2
Breganze 2
Chengdu 2
Erbè 2
Fairfield 2
Fremont 2
Fuzhou 2
Helsinki 2
Houston 2
Lanzhou 2
Misterbianco 2
San Mateo 2
Venaria Reale 2
Alexandria 1
Bari 1
Boydton 1
Catania 1
College Station 1
Cormano 1
Cosenza 1
Dalian 1
Gioia del Colle 1
Hangzhou 1
Hebei 1
Hefei 1
Kiev 1
Lappeenranta 1
Liverpool 1
Lviv 1
Mykolayiv 1
New York 1
Palermo 1
Pavia 1
Poltava 1
Poona 1
Seattle 1
Seoul 1
Strasbourg 1
Taipei 1
Vittoria 1
Woodbridge 1
Wuhan 1
Totale 1.503
Salva come PNG Salva come JPEG
Nome #
1. Real World Evidence vs. Real World Data: definizioni e razionale 125
Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study 92
Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: a population-based case control study 83
In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: A population-based study 73
Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study 73
12. Real World Evidence nelle valutazioni post‑marketing su farmaci generici e biosimilari 66
Analgesic drug use in elderly persons: A population-based study in Southern Italy 60
Direct healthcare costs of chronic kidney disease management in Italy: What cost-savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis-stimulating agents? 58
Medication is an additional source of phosphate intake in chronic kidney disease patients 56
Pattern of Use of Biosimilar and Originator Somatropin in Italy: A Population-Based Multiple Databases Study During the Years 2009-2014 56
Psoriasis and psoriasiform reactions secondary to Immune Checkpoint Inhibitors 55
The Burden of Nephrotoxic Drug Prescriptions in Patients with Chronic Kidney Disease: A Retrospective Population-Based Study in Southern Italy 50
Challenges in Post-marketing Studies of Biological Drugs in the Era of Biosimilars: A Report of the International Society for Pharmacoepidemiology 2019 Mid-Year Meeting in Rome, Italy 49
How Have Intravitreal Anti-VEGF and Dexamethasone Implant Been Used in Italy? A Multiregional, Population-Based Study in the Years 2010–2016 46
Chronic Kidney Disease Requiring Healthcare Services: A New Approach to Evaluate Epidemiology of Renal Disease 44
In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study 44
Are Patients with Psoriasis and Psoriatic Arthritis Undertreated? A Population-Based Study from Southern Italy 42
Recent advances in the management of chemotherapy-induced neutropenia: Biosimilar granulocyte colony-stimulating factor use in Italy 41
How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009–2014 40
Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study 38
Comparison of Direct Oral Anticoagulant Use for the Treatment of Non-Valvular Atrial Fibrillation in Pivotal Clinical Trials vs. the Real-World Setting: A Population-Based Study from Southern Italy 38
Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project 38
How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013 37
null 37
The economic burden of preventable adverse drug reactions: a systematic review of observational studies 37
Kidney disease in diabetic patients: From pathophysiology to pharmacological aspects with a focus on therapeutic inertia 37
Biosimilars in Italy: What do real-world data reveal? 36
Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease 36
Antidepressants and the Risk of Cardiovascular Events in Elderly Affected by Cardiovascular Disease: A Real-Life Investigation From Italy 35
Characteristics and Absolute Survival of Metastatic Colorectal Cancer Patients Treated With Biologics: A Real-World Data Analysis From Three European Countries 33
Cancer Patients at Risk for Medication-Related Osteonecrosis of the Jaw. A Case and Control Study Analyzing Predictors of MRONJ Onset 32
Quanto sono utilizzati in Italia i farmaci biosimilari? Uno studio retrospettivo sull'uso degli agenti stimolanti l'eritropoiesi negli anni 2009-2013 29
Erratum: In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: A population-based study (BMC Nephrology (2019) 20 (359) DOI: 10.1186/s12882-019-1554-0) 29
null 28
Adverse drug reactions associated with off-label use of ketorolac, with particular focus on elderly patients. An analysis of the Italian pharmacovigilance database and a population based study 28
Neoplastic implications in patients suffering from hidradenitis suppurativa under systemic treatments 28
The advent of biosimilars for the treatment of diabetes: current status and future directions 26
Efficacy of Systemic Biologic Drugs in Pediatric Psoriasis: Evidence From Five Selected Randomized Clinical Trials 26
null 24
Incidence of Skin Cancer in Patients With Chronic Inflammatory Cutaneous Diseases on Targeted Therapies: A Systematic Review and Meta-Analysis of Observational Studies 24
Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. 23
Pharmacokinetics of new oral anticoagulants: implications for use in routine care 20
null 19
Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence. 19
null 18
null 17
The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand? 17
Vitiligo-like Lesions and COVID-19: Case Report and Review of Vaccination- and Infection-Associated Vitiligo 16
Safety and potential interaction of immunosuppressive drugs for the treatment of inflammatory bowel disease in elderly patients 12
Non-Motherhood between Obligation and Choice: Statistical Analysis Based on Permutation Tests of Spontaneous and Induced Abortion Rates in the Italian Context 6
Hidradenitis suppurativa and psoriasis: the odd couple 3
Hidradenitis Suppurativa in Patients with HIV: A Scoping Review 2
Totale 2.001
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.009
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.009
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201926 0 0 2 9 11 3 1 0 0 0 0 0
2019/202099 0 1 0 2 1 10 3 4 2 22 10 44
2020/2021355 6 8 50 42 30 10 19 20 34 28 1 107
2021/2022373 2 23 2 4 16 8 44 5 24 80 33 132
2022/2023986 70 104 36 83 76 92 16 36 430 7 24 12
2023/202476 20 30 26 0 0 0 0 0 0 0 0 0
Totale 2.001